Hypoactive sexual desire disorder (HSDD) is the absence of sexual thoughts and fantasies causing low libido and sex drive in women population worldwide.
This report contains market size and forecasts of Hypoactive Sexual Desire Disorder (HSDD) Treatment in Global, including the following market information:
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hypoactive Sexual Desire Disorder (HSDD) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Buspirone Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hypoactive Sexual Desire Disorder (HSDD) Treatment include AMAG Pharmaceuticals, Allergan, Plc., Ivix LLX, EndoCeutics, Inc., Emotional Brain BV, S1 Biopharma, Inc. and Sprout Pharmaceuticals, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hypoactive Sexual Desire Disorder (HSDD) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Segment Percentages, by Type, 2021 (%)
Buspirone
Bupropion
Testosterone
Flibanserin
Bremelanotide
Cognitive Behavior Therapy
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinic
Others
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hypoactive Sexual Desire Disorder (HSDD) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hypoactive Sexual Desire Disorder (HSDD) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AMAG Pharmaceuticals
Allergan, Plc.
Ivix LLX
EndoCeutics, Inc.
Emotional Brain BV
S1 Biopharma, Inc.
Sprout Pharmaceuticals, Inc.